Log in

OTCMKTS:NWBONorthwest Biotherapeutics Stock Price, Forecast & News

+0.01 (+3.20 %)
(As of 06/2/2020 04:00 PM ET)
Today's Range
Now: $0.32
50-Day Range
MA: $0.21
52-Week Range
Now: $0.32
Volume1.85 million shs
Average Volume3.16 million shs
Market Capitalization$222.06 million
P/E RatioN/A
Dividend YieldN/A
Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:NWBO
Previous SymbolNASDAQ:NWBO



Sales & Book Value

Annual Sales$2.41 million
Book Value($0.07) per share


Net Income$-20,300,000.00
Net Margins-842.16%


Market Cap$222.06 million
Next Earnings Date6/5/2020 (Estimated)
OptionableNot Optionable

Receive NWBO News and Ratings via Email

Sign-up to receive the latest news and ratings for NWBO and its competitors with MarketBeat's FREE daily newsletter.

Northwest Biotherapeutics (OTCMKTS:NWBO) Frequently Asked Questions

How has Northwest Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Northwest Biotherapeutics' stock was trading at $0.1799 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NWBO shares have increased by 79.1% and is now trading at $0.3222. View which stocks have been most impacted by Coronavirus.

When is Northwest Biotherapeutics' next earnings date?

Northwest Biotherapeutics is scheduled to release its next quarterly earnings announcement on Friday, June 5th 2020. View our earnings forecast for Northwest Biotherapeutics.

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) announced its quarterly earnings data on Monday, March, 16th. The biotechnology company reported $0.01 EPS for the quarter. The biotechnology company earned $0.90 million during the quarter. View Northwest Biotherapeutics' earnings history.

Has Northwest Biotherapeutics been receiving favorable news coverage?

News headlines about NWBO stock have trended extremely negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Northwest Biotherapeutics earned a daily sentiment score of -4.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutNorthwest Biotherapeutics.

Who are some of Northwest Biotherapeutics' key competitors?

What other stocks do shareholders of Northwest Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), Zeltiq Aesthetics (ZLTQ), Avid Bioservices (CDMO), Amarin (AMRN), TransEnterix (TRXC), Kura Oncology (KURA), Novavax (NVAX) and Synergy Pharmaceuticals (SGYP).

Who are Northwest Biotherapeutics' key executives?

Northwest Biotherapeutics' management team includes the following people:
  • Ms. Linda F. Powers J.D., Chairperson, CEO, Pres & CFO (Age 63)
  • Dr. Alton L. Boynton, Founder, Chief Scientific Officer, Sec. & Director (Age 74)
  • Dr. Marnix L. Bosch M.B.A., Ph.D., MBA, Chief Technical Officer (Age 60)
  • Mr. Leslie J. Goldman, Sr. VP & Gen. Counsel (Age 74)
  • Mr. David Innes, VP of Investor Relations

What is Northwest Biotherapeutics' stock symbol?

Northwest Biotherapeutics trades on the OTCMKTS under the ticker symbol "NWBO."

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Northwest Biotherapeutics' stock price today?

One share of NWBO stock can currently be purchased for approximately $0.32.

How big of a company is Northwest Biotherapeutics?

Northwest Biotherapeutics has a market capitalization of $222.06 million and generates $2.41 million in revenue each year. Northwest Biotherapeutics employs 14 workers across the globe.

What is Northwest Biotherapeutics' official website?

The official website for Northwest Biotherapeutics is www.nwbio.com.

How can I contact Northwest Biotherapeutics?

Northwest Biotherapeutics' mailing address is 4800 MONTGOMERY LANE SUITE 800, BETHESDA MD, 20814. The biotechnology company can be reached via phone at 240-497-9024 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.